Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Fernandes

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Microbiological Methods|April 30, 2021
Quantification of biofilm produced by clinical, environment and hands' isolates Klebsiella species using colorimetric and classical methodsNagela Bernadelli Sousa Silva, Priscila Guerino Vilela Alves, Lara de Andrade Marques, et al.
Therapeutic Advances in Gastroenterology|September 14, 2019
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabFernando Magro, Susana Lopes, Marco Silva, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
EARLY INTERVENTION PREVENTS DISEASE PROGRESSION IN ULCERATIVE COLITIS - A MULTICENTER RETROSPECTIVE STUDYJoana Camões Neves, Tiago Leal, Samuel Fernandes, et al.
Expert Review of Clinical Immunology|January 3, 2025
Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT)Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, et al.
The American Journal of Gastroenterology|February 2, 2024
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational StudyGabriele Dragoni, Tommaso Innocenti, Aurelién Amiot, et al.
Inflammatory Bowel Diseases|January 21, 2017
Impact of Early Surgery and Immunosuppression on Crohn's Disease Disabling OutcomesFernando Magro, Cláudia C Dias, Rosa Coelho, et al.
Journal of Crohn'S & Colitis|September 30, 2016
Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic InterventionsCláudia Camila Dias, Pedro Pereira Rodrigues, Rosa Coelho, et al.
Journal of Crohn'S & Colitis|January 20, 2024
Prophylactic Versus Endoscopy-driven Treatment of Crohn's Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study]Jeroen Geldof, Marie Truyens, Michiel Hanssens, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Microbiological Methods|April 30, 2021
Quantification of biofilm produced by clinical, environment and hands' isolates Klebsiella species using colorimetric and classical methodsNagela Bernadelli Sousa Silva, Priscila Guerino Vilela Alves, Lara de Andrade Marques, et al.
Therapeutic Advances in Gastroenterology|September 14, 2019
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabFernando Magro, Susana Lopes, Marco Silva, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
EARLY INTERVENTION PREVENTS DISEASE PROGRESSION IN ULCERATIVE COLITIS - A MULTICENTER RETROSPECTIVE STUDYJoana Camões Neves, Tiago Leal, Samuel Fernandes, et al.
Expert Review of Clinical Immunology|January 3, 2025
Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT)Suzete Costa, João Pedro Aguiar, Mónica D Oliveira, et al.
The American Journal of Gastroenterology|February 2, 2024
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational StudyGabriele Dragoni, Tommaso Innocenti, Aurelién Amiot, et al.
Inflammatory Bowel Diseases|January 21, 2017
Impact of Early Surgery and Immunosuppression on Crohn's Disease Disabling OutcomesFernando Magro, Cláudia C Dias, Rosa Coelho, et al.
Journal of Crohn'S & Colitis|September 30, 2016
Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic InterventionsCláudia Camila Dias, Pedro Pereira Rodrigues, Rosa Coelho, et al.
Journal of Crohn'S & Colitis|January 20, 2024
Prophylactic Versus Endoscopy-driven Treatment of Crohn's Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study]Jeroen Geldof, Marie Truyens, Michiel Hanssens, et al.
Pageof 4